About This Trial
Combination of subcutaneous PD-1 inhibitor with BCMA-CD3 bispecific antibody for heavily pretreated myeloma.
Primary Endpoints
- Progression-free survival
- Overall response rate
Latest Update
January 2026
Early cohort shows 68% overall response rate with manageable safety profile. Enrollment ahead of schedule.